Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2509-4254
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib ; day:27 ; month:4 ; year:2017 ; pages:1-8
PharmacoEconomics - open ; (27.4.2017), 1-8
- Keyword
-
Krebs
Onkologie
- Creator
-
Mahlich, Jörg
- Contributor
-
Okamoto, Shinichiro
Tsubota, Akiko
SpringerLink (Online service)
- DOI
-
10.1007/s41669-017-0024-5
- URN
-
urn:nbn:de:1111-201705096901
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:20 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mahlich, Jörg
- Okamoto, Shinichiro
- Tsubota, Akiko
- SpringerLink (Online service)
Other Objects (12)
Ibrutinib dose modifications in the management of CLL
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Engineered extracellular vesicles for immunotherapy of chronic lymphocytic leukemia (CLL)
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
Cost of illness and economic burden of chronic lymphocytic leukemia
CLL-Therapie mit Ibrutinib : 30 Fragen und Antworten für Ärzte
Fallbeispiele Ibrutinib : orale zielgerichtete Behandlung der Chronischen Lymphatischen Leukemie (CLL)
Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL
Ibrutinib dose modifications in the management of CLL
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Engineered extracellular vesicles for immunotherapy of chronic lymphocytic leukemia (CLL)
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
Cost of illness and economic burden of chronic lymphocytic leukemia
CLL-Therapie mit Ibrutinib : 30 Fragen und Antworten für Ärzte
Fallbeispiele Ibrutinib : orale zielgerichtete Behandlung der Chronischen Lymphatischen Leukemie (CLL)
Ibrutinib : eine neue orale Therapieoption bei CLL und beim MCL
Ibrutinib dose modifications in the management of CLL
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
Engineered extracellular vesicles for immunotherapy of chronic lymphocytic leukemia (CLL)
Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia
Cost of illness and economic burden of chronic lymphocytic leukemia
CLL-Therapie mit Ibrutinib : 30 Fragen und Antworten für Ärzte
Fallbeispiele Ibrutinib : orale zielgerichtete Behandlung der Chronischen Lymphatischen Leukemie (CLL)